SAB Biotherapeutics, Inc. SABS
3.18 USD +0.06 (+1.92%)
At closeNov 4, 2026, 4:02 PM EST
3.18 0.00 0.00%
After hours · Nov 4, 4:02 PM ET
3.09 Day range 3.34
2.49 52-week range 4.59
- YTD
- -14.97%
- 1 year
- -2.15%
Financial health
Altman Z-Score
6.69 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 4
- P/B 4
Valuation
P/E 17.0×
FY 2019 5y median -1.0× FY 2025
P/S 0.0×
FY 2019 5y median 3.5× FY 2025
P/B 0.5×
FY 2019 5y median 0.8× FY 2025
P/FCF -1.6×
FY 2019 5y median -1.5× FY 2025
EV/EBITDA 4.1×
FY 2019 5y median -1.1× FY 2025
EV/Sales 0.0×
FY 2019 5y median 0.7× FY 2025
FCF Yield -63.3%
FY 2019 5y median -66.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019 5y median -121.0% FY 2025
Net Margin 0.0%
FY 2019 5y median -78.4% FY 2025
ROE 8.8%
FY 2019 5y median -60.3% FY 2025
ROIC -30.0%
FY 2019 5y median -50.8% FY 2025
ROA 7.7%
FY 2019 5y median -36.8% FY 2025
Growth (YoY)
Revenue -100.0%
FY 2019 FY 2025
Operating Income -14.1%
FY 2019 FY 2025
EPS (diluted) 78.5%
FY 2019 FY 2025
Free Cash Flow -32.0%
FY 2019 FY 2025
Financial Health
Current Ratio 9.5×
FY 2019 5y median 3.0× FY 2025
Quick Ratio 9.5×
FY 2019 5y median 3.0× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.2× FY 2025
Net Debt / EBITDA -0.3×
FY 2019 5y median 0.6× FY 2025
Interest Coverage -203×
FY 2019 5y median -121× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31